| Literature DB >> 32210166 |
Philipp Klein1, Patrick Johe2, Annika Wagner3, Sascha Jung2,4, Jonas Kühlborn1, Fabian Barthels2, Stefan Tenzer5, Ute Distler5, Waldemar Waigel6, Bernd Engels6, Ute A Hellmich3,7, Till Opatz1, Tanja Schirmeister2.
Abstract
Electrophilic (het)arenes can undergo reactions with nucleophiles yielding π- or Meisenheimer (σ-) complexes or the products of the SEntities:
Keywords: Meisenheimer complex; cysteine protease; electrophilic (het)arene; nucleophilic aromatic substitution; prodrug; rhodesain; π-complex
Mesh:
Substances:
Year: 2020 PMID: 32210166 PMCID: PMC7145299 DOI: 10.3390/molecules25061451
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of the dipeptide sequence of new protease inhibitors.
Scheme 2Syntheses of potential protease inhibitors of the general structure R-NH-l-Phe-l-Leu-OBn with (hetero)aromatic units (R).
Scheme 3Synthesis of acid 8 (R-NH-l-Phe-l-Leu-OH).
Figure 1Dependence of inhibition potency (IC50 values) on substrate concentration for inhibition of cathepsin L by compound 7. Increasing IC50 values at increasing substrate concentrations indicate a competitive inhibition mode.
Inhibition data for inhibitors of the general structure R-NH-l-Phe-l-Leu-OBn, % inhibition at 20 µM and [µM] 1.
| Cpd. | Cath. L | Cath. B | Rhod. | DENV PR | Sortase A |
|---|---|---|---|---|---|
| % inh./ | % inh./ | % inh./ | % inh./ | % inh./ | |
|
| 57/nd | 16/nd | nd/nd | 19/nd | nd/nd |
|
| 56/nd | 33/nd | nd/nd | 24/nd | nd/nd |
|
| 60/nd | 22/nd | nd/nd | 28/nd | nd/nd |
|
| 99/0.66 | 20/nd | 75/0.29 | 10/nd | 11/nd |
|
| 8/nd | 10/nd | nd/nd | 11/nd | nd/nd |
|
| 50/nd | 21/nd | nd/nd | 12/nd | nd/nd |
|
| 98/1.6 | 63/4.4 | 45/nd | 31/nd | 16/nd |
1 All values are from at least three independent measurements; standard deviations are 10% or less; nd, not determined; cpd., compound; Cath. L, cathepsin L; Cath. B, cathepsin B; Rhod.; rhodesain, DENV PR, Dengue virus protease.
Figure 2Inhibition of rhodesain by compound 8.
Figure 319F NMR spectra: (a) Ester 7 and acid 8 are readily distinguishable by their chemical shifts. (b) Time-resolved 19F NMR shows rhodesain-dependent turnover of 7 into 8. As a control, a separate spectrum of the expected amount of compound 8 that should have formed from 7 in the NMR-based enzymatic assay is recorded (blue trace). Due to the poor solubility of compound 7 (compare (a)), no peak was observed within the 128 scans run for each time-trace. Upon addition of rhodesain, the turbid sample gradually turned clear and the resonance for compound 8 appeared. Therefore, the spectral region has been confined to that displaying the chemical shift for compound 8. (c) Acid 8 forms a stable complex (asterisk) with rhodesain. The peak intensity depends on the amount of protein. For reference, the spectrum of free compound 8 (blue) is included (as shown in (a)).
Figure 4ESI-MS mass spectra of rhodesain ([M + 11 H]11+ at m/z 2109.9 +/– 20 ppm) in the absence (orange) or presence (blue) of compounds 4 (A), 7 (B) and 8 (C).
Figure 5Chromatograms and mass spectra of the LC–MS runs of compound 7 preincubated with (a) buffer or (b) buffer and catalytically active rhodesain. The elution peaks and mass signals of the unconverted ester 7 are presented in orange, the signals of the resulting acid 8 are highlighted in blue.
Scheme 4Reaction of compound 7 with 2-phenylethanethiol and observed products.
Stabilities (only thiolate/thiolate and imidazolium: full optimization/thiolate and imidazolium: R(S-CX) fixed at 1.9 Å) of the Meisenheimer complexes in a polar solvent [in kcal/mol]. For all calculations the 6-31 + G* basis sets were employed. For further information see main text and Figure 6.
| Structure | ωB97XD | MP2 | SCS-MP2 |
|---|---|---|---|
| Pre-complex | –8.8/–9.0/ | –12.3/–16.0/- | –10.3/–12.8/ |
| S-CH | +0.8/–11.5/–6.8 | –6.6/–16.0/–12.8 | –4.1/–12.9/–9.3 |
| S-CF | –3.3/–13.1/–3.1 | –13.2/–20.3/–12.5 | –11.1/–16.5/–10.1 |
| S-NO2 | –2.7/–9.3/+3.3 | –11.9/–17.0/–5.3 | –9.1/–13.3/–2.9 |
Figure 6Computed structures and 19F shifts relative to the 19F shift of the free inhibitor for the different model systems. For the undistorted inhibitor the following distances are obtained: R(CAr…F) = 1.35 Å, R(CAr…NO2) = 1.47 Å and R(CAr…H) = 1.085 Å. For further explanation see main text; 1 with respect to the NO2 group in meta-position to F; 2 with respect to the NO2 group in para-position to F. MP2, second-order Møller–Plesset perturbation theory.
Figure 7Substrate-like binding mode of ester 7. Light grey: solvent accessible surface of rhodesain; magenta: carbon atoms of rhodesain amino acid residues; orange: carbon atoms of ester 7; blue: nitrogen; red: oxygen; yellow: sulfur; cyan: fluorine.
Figure 8Fluctuations in the distance between the sulfur center of Cys-25 and (a) the carbon center of the ester group of compound 7 and (b) the carbon center of the acid group. The simulations were started from the pose given in Figure 7.
Figure 9Predicted binding mode of acid 8. Light grey: solvent accessible surface of rhodesain; magenta: carbon atoms of rhodesain amino acid residues; green: carbon atoms of acid 8; blue: nitrogen; red: oxygen; yellow: sulfur; cyan: fluorine.
Figure 10Charts (a,b) present the fluctuation of the distances between the sulfur center of Cys-25 and the carbon centers (CX) of the aromatic ring: (a) = distance SCH; (b) = SCNO2. (c,d) give the fluctuation in the distance of the Cys-SH-N hydrogen bond along MD 5 (c) and MD 6 (d). All simulations start from the pose in Figure 9.
Figure 11Sketch of the two principle conformations of acid 8 taken along the molecular dynamics (MD) simulations starting from the pose depicted in Figure 9. The electrophilic aromatic ring is given in atomic color while the rest of the inhibitor is given in blue or red. The distances between the S-center of Cys-25 and the NH group (Cys-SH-N) are given in black, while the distances to the CH group of the aromatic ring (Cys-SH-C) are given in red. For more information, see main text.
Shapes of various addition–reaction pathways of the Cys moiety to the substituted aromatic rings. Relative energies [kcal/mol] are given with respect to the full geometry optimization. The full optimization started from the indicated MD frame.
| Starting Structure | R(S-CNO2) | R(S-CH) | ΔE |
|---|---|---|---|
| MD 6 Frame 963 | 3.7 | 0.0 | |
| 3.3 | 1.4 | ||
| 3.1 | 1.7 | ||
| 2.9 | 2.5 | ||
| MD 6 Frame 1096 | 3.7 | 0.0 | |
| 3.3 | 0.7 | ||
| 3.1 | 0.8 | ||
| 2.9 | 2.6 | ||
| MD 6 Frame 542 | 4.9 | 0.0 | |
| 4.5 | 1.2 | ||
| 4.1 | 3.4 | ||
| 3.9 | 0.4 | ||
| 3.5 | 5.3 |
Figure 12Anti-trypanosomal activity of the (a) benzyl ester 7 and (b) acid 8 measured by the ATPlite assay. Shown is luminescence (RLU/s = relative light unit per second) in dependence of compound concentration.